Study

The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. – Cost Effective Supplements

The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone.

Quick navigation


http://www.ncbi.nlm.nih.gov/pubmed/22774396


Conclusion of this study

The combined administration of MI and DCI in physiological plasma ratio (40:1) should be considered as the first line approach in PCOS overweight patients, being able to reduce the metabolic and clinical alteration of PCOS and, therefore, reduce the risk of metabolic syndrome.


Supplements analyzed in this study

Inositol

Health conditions analyzed in this study

Polycystic Ovary Syndrome


Moderately Positive
Inositol


Functions related to this study

Heart health


Slightly Positive
Inositol

Insulin control


Slightly Positive
Inositol

Weight loss


Slightly Positive
Inositol

Women's health


Moderately Positive
Inositol


Body systems related to this study


Cardiovascular System

Digestive System

Endocrine System

Reproductive System
Scroll to top